Company: AstraZeneca (AZN)
Drug/indication: Zibotentan for prostate cancer
Estimated timing: Fourth quarterRecent stock performance: A rebound in June and July has pushed the stock up 6% for the year. Zibotentan represents the biggest, near-term competitive threat to Dendreon's (DNDN) prostate cancer immunotherapy Provenge. The phase III study of zibotentan targets the same patient population described in Provenge's FDA-approved label -- men with prostate cancer that no longer respond to hormone treatment but who have minimal bone pain and have not yet started chemotherapy. The study of 580 men compares treatment with zibotentan against best supportive care with a primary endpoint of overall survival. If the study is positive and zibotentan gains FDA approval, doctors will have another treatment choice besides Provenge for this group of prostate cancer patients.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV